

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 209/42, 307/84, A61K 31/40, 31/34		A1	(11) International Publication Number: WO 99/25684 (43) International Publication Date: 27 May 1999 (27.05.99)
(21) International Application Number: PCT/IB98/01672			ington, CT 06359 (US). ALLEN, Douglas, John, Meldrum [US/US]; 549 Ocean Avenue, New London, CT 06320 (US).
(22) International Filing Date: 21 October 1998 (21.10.98)			(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).
(30) Priority Data: 60/065,422 13 November 1997 (13.11.97) US 60/074,266 10 February 1998 (10.02.98) US			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).			
(72) Inventors; and			Published
(75) Inventors/Applicants (for US only): RAGAN, John, Anthony [US/US]; 1 Lark Lane, Gales Ferry, CT 06335 (US). MAKOWSKI, Teresa, Woodall [US/US]; 379 Forsyth Road, Salem, CT 06420 (US). AM ENDE, David, Jon [US/US]; 163 Niantic River Road, Waterford, CT 06385 (US). CLIFFORD, Pamela, Jane [US/US]; 34 Lewis Road, Preston, CT 06365 (US). YOUNG, Gregory, Randall [US/US]; 18 Friar Tuck Drive, Gales Ferry, CT 06335 (US). CONRAD, Alyson, Kay [US/US]; 8 Rosemarie Court, Ledyard, CT 06339 (US). EISENBEIS, Shane, Allen [US/US]; 3 Holly Court, Pawcatuck, CT 06379 (US). QUALLICH, George, Joseph [US/US]; 349 Norwich-Westerly Road, North Ston-			With international search report.
(54) Title: METHOD OF SYNTHESIS OF PYRROLE AMIDES			
(57) Abstract			
A method for preparing pyrrole-carboxyamides which selectively bind to GABAa receptors; which comprises reacting 1,3-cycloakandiones with bromoethylacetate followed by reaction of the resulting product with an acid halide followed by reaction with an aromatic amine and finally with an ammonium source at an elevated temperature.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD OF SYNTHESIS OF PYRROLE AMIDESBackground of the Invention5 Field of the Invention

This invention relates a method for synthesis of novel fused pyrrolecarboxamides which selectively bind to GABAa receptors. This invention also relates to chemical intermediates for synthesis of such compounds. Compounds which bind to GABAa receptors are useful in treating anxiety, sleep and seizure disorders, and overdoses of benzodiazepine-type drugs, and enhancing alertness.

10 Description of the Related Art

γ -Aminobutyric acid (GABA) is regarded as one of the major inhibitory amino acid transmitters in the mammalian brain. Over 30 years have elapsed since its presence in the brain was demonstrated (Roberts & Frankel, *J. Biol. Chem.* 187: 55-63, 1950; Udenfriend, *J. Biol. Chem.* 187: 65-69, 1950). Since that time, an enormous amount of effort has been devoted to implicating GABA in the etiology of seizure disorders, sleep, anxiety and cognition (Tallman and Gallager, *Ann. Rev. Neuroscience* 8: 21-44, 1985). Widely, although unequally, distributed through the mammalian brain, GABA is said to be a transmitter at approximately 30% of the synapses in the brain. In most regions of the brain, GABA is associated with local inhibitory neurons and only in two regions is GABA associated with longer projections. GABA mediates many of its actions through a complex of proteins localized both on cell bodies and nerve endings; these are called GABAa receptors. Postsynaptic responses to GABA are mediated through alterations in chloride conductance that generally, although not invariably, lead to hyperpolarization of the cell. Recent investigations have indicated that the complex of proteins associated with postsynaptic GABA responses is a major site of action for a number of structurally unrelated compounds capable of modifying postsynaptic responses to GABA. Depending on the mode of interaction, these compounds are capable of producing a spectrum of activities (either sedative, anxiolytic, and anticonvulsant, or wakefulness, seizures, and anxiety).


1,4-Benzodiazepines continue to be among the most widely used drugs in the world. Principal among the benzodiazepines marketed are chlordiazepoxide, diazepam, flurazepam, and triazolam. These compounds are widely used as anxiolytics, sedative-hypnotics, muscle relaxants, and anticonvulsants. A number of

these compounds are extremely potent drugs; such potency indicates a site of action with a high affinity and specificity for individual receptors. Early electrophysiological studies indicated that a major action of benzodiazepines was enhancement of GABAergic inhibition. The benzodiazepines were capable of enhancing presynaptic inhibition of a monosynaptic ventral root reflex, a GABA-mediated event (schmidt et al., 1967, Arch. Exp. Path. Pharmakol. 258: 69-82). All subsequent electrophysiological studies (reviewed in Tallman et al. 1980, Science 207: 274-81, Haefley et al., 1981, Handb. Exptl. Pharmacol. 33: 95-102) have generally confirmed this finding, and by the mid-1970s, there was a general consensus among electrophysiologists that the benzodiazepines could enhance the actions of GABA.

With the discovery of the "receptor" for the benzodiazepines and the subsequent definition of the nature of the interaction between GABA and the benzodiazepines, it appears that the behaviorally important interactions of the benzodiazepines with different neurotransmitter systems are due in a large part to the enhanced ability of GABA itself to modify these systems. Each modified system, in turn, may be associated with the expression of a behavior.

Studies on the mechanistic nature of these interactions depended on the demonstration of a high-affinity benzodiazepine binding site (receptor). Such a receptor is present in the CNS of all vertebrates phylogenetically newer than the boney fishes (Squires & Braestrup 1977, Nature 166: 732-34, Mohler & Okada, 1977, Science 198: 854-51, Mohler & Okada, 1977, Br.J.Psychiatry 133: 261-68). By using tritiated diazepam, and a variety of other compounds, it has been demonstrated that these benzodiazepine binding sites fulfill many of the criteria of pharmacological receptors; binding to these sites in in vitro is rapid, reversible, stereospecific, and saturable. More importantly, highly significant correlations have been shown between the ability of benzodiazepines to displace diazepam from its binding site and activity in a number of animal behavioral tests predictive of benzodiazepine potency (Braestrup & Squires 1978, Br. J. Psychiatry 133: 261-68). The average therapeutic doses of these drugs in man also correlate with receptor potency (Tallman et al. 1980, Science 207: 274-281).

Certain fused pyrrolecarboxamides which are useful as GABA brain receptor ligands are disclosed in United States Patent 5,484,944 which is hereby incorporated by reference. These compounds may be prepared by the scheme shown below.




wherein z is N-R or a carbon atom substituted with R groups; and W is an optionally substituted aromatic ring.

5


Summary of the Invention

This invention provides a method for preparing a compound of the formula
10



wherein R¹ and R² are independently selected from hydrogen and C₁ - C₆ alkyl; and Ar is phenyl or heterocycle; or phenyl or heterocycle substituted with up to three substituents selected from C₁ - C₆ alkoxy, C₁ - C₆ alkyl, C₂ - C₆ alkenyl, C₁ - C₆ perflouroalkyl, C₁ - C₆ alkoxy, C₁ - C₆ perfluoroalkoxy, F, Cl, Br, -O-(CH₂)_k-O-, or 5 (CH₂)_m NR¹R²; wherein
 n is an integer selected from 0 to 2;
 m is an integer selected from 0 to 6; and
 k is an integer selected from 1 or 2;
 which comprises:


10 1) Reacting a compound of the formula



with an excess of an acid chloride or anhydride in a reaction inert solvent containing an excess of an acid acceptor until reaction is complete;

15 2) Adding an equivalent amount of NH₂-Ar to the solution of step 1 and holding until reaction is complete.

This invention also provides a method for preparing a compound of the formula



20 which comprises:

reacting a compound of formula II with an excess of an ammonium source in a reaction inert solvent at an elevated temperature until reaction is complete.

This invention also provides a method for preparing a compound of formula III wherein Ar is 2-fluoro-4-methoxy phenyl, (4-methyl-N-t-butylcarbamic ester)-amino methyl phenyl, 4-ethoxy phenyl or 4-methoxyphenyl, 4-fluorophenyl, 4-pyridyl or 3-pyridyl, b-(2-hydroxyethoxy)-3-pyridyl, benzo[1, 3] dioxol-5-yl.

5 This invention also provides a method for preparing a compound of formula I wherein n is 2 and R¹ and R² are hydrogen; n is 1 and R¹ and R² are methyl; n is one and R¹ and R² are hydrogen; n is zero and R¹ and R² are hydrogen; and n is 1, R¹ is methyl and R² is hydrogen.

In another aspect this invention provides the compound of formula 1 which is 4-Oxo-10 5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid, 4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide, 6,6-Dimethyl-4-oxo-4,5,6,7-tetrahydro-benofuran-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide, 4-[(4-Oxo-4,5,6,7-tetrahydro-benzofuran-3-carbonyl)-amino]-benzyl-methyl-carbamic acid tert-butyl ester,

15 4-[(4-Oxo-4,5,6,7-tetrahydro-1H-indole-3-carbonyl)-amino]-benzyl-methyl-carbamic acid tert-butyl ester,

4-Oxo-5,6-dihydro-4H-cyclopenta[b]furan-3-carboxylic acid (4-ethoxy-phenyl)-amide,

4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid

20 benzo[1,3]dioxol-5-ylamide,

4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid-(4-methoxy-phenyl)-amide,

6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid (4-fluoro-phenyl)-amide,

25 6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid pyridin-4-ylamide,

6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid pyridin-3-ylamide,

6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid [6-(2-hydroxy-30 ethoxy)-pyridin-3-yl]-amide, and

4-Oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (4-methylaminomethyl-phenyl)-amide.

This invention also provides the intermediate compounds:


(4-Nitrobenzyl)-methyl-carbamic acid tert-butyl ester, and

(4-Aminobenzyl)-methyl-carbamic acid tert-butyl ester.

This invention also provides a method of preparing a compound of Formula III wherein:

Ar is substituted with $-(CH_2)_m NH R^1$ which comprises:

5 reacting a compound of the formula




with water in the presence of acid.

Detailed Description of the Invention

10

The method of this invention is illustrated by the scheme shown below.



15

wherein Ar, R¹, R² and n are as defined above.

Compounds of formula II are readily prepared by reacting the appropriate 1,3-diketone with halo pyruvic acid ester, preferably ethylbromopyruvate as described in U.S. Patent No. 5,484,944 and general procedure A of Example 1 of the present invention.

Compound I is prepared from compound II by converting the carboxylic acid group of compound I to the mixed acid anhydride and thence to the carboxanilide by reaction of the acid anhydride with the selected aniline in the presence of base. The reaction is preferably carried out in a reaction inert solvent at a reduced temperature

5 without isolation of the intermediate acid anhydride.

Any acid chloride or anhydride may be used to form the mixed acid anhydride, ethylchloroformate is a preferred reagent.

The above-reaction is illustrated in general procedure B of Example 1 below.

Conversion of compound I to the final product (compound III) is accomplished


10 by reaction of compound I with an ammonium salt in a reaction inert solvent at an elevated temperature adequate to insure reaction in a reasonable period of time. Any polar reaction inert solvent is suitable; n-methyl pyrrolidine is preferred. Ammonium acetate is a convenient source of ammonium ion.

This procedure is illustrated in general procedure C of Example 1 below.

15 Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention, as demonstrated by the following examples. In some cases protection of certain reactive functionalities may be necessary to achieve some of the above transformations. In general the need for such protecting groups will be

20 apparent to those skilled in the art of organic synthesis as well as the conditions necessary to attach and remove such groups.

The invention is illustrated further by the following examples which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them.

Example 1

5 4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid

General Procedure A (diketone to furan carboxylic acid):

Cycloheptane-1,3-dione (22.1 g, 174 mmol) was dissolved in 176 mL of isopropanol and cooled to 0 °C. Ethyl bromopyruvate (21.9 mL, 174 mmol) was added, followed by K_2CO_3 (24.2 g, 175 mmol). The solution was then allowed to warm to room temperature and stirred for 16 hours. 220 mL of water were added, and the solution was extracted with four 110 mL portions of dichloromethane. The combined organic extracts were then washed with brine, and concentrated to provide an orange-brown oil. 220 mL of 1 N H_2SO_4 was then added, and the solution warmed in an 85 °C oil bath for 16 hours. After cooling to room temperature, the solution was extracted with two 220 mL portions of dichloromethane. The combined organic extracts were washed with brine, and concentrated to provide 37.2 g of a tan solid. This crude product was then granulated with 170 mL of methyl t-butyl ether, warming nearly to reflux for 30 min, followed by stirring at room temperature for 16 hours. Filtration provided the product as an off-white solid, 14.6 g (75 mmol, 43% yield from the diketone).

25 ^1H nmr (CDCl_3): 8.07 (s, 1H), 3.14-3.10 (m, 2H), 2.89-2.86 (m, 2H), 2.05-1.93 (m, 4H).

MS (Cl): 195 (M+1, 100)

4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide

General Procedure B (furan carboxylic acid to furan carboxamide):

5 A solution of furan acid from Procedure A (7.65 g, 39.4 mmol) was dissolved in 80 mL dichloromethane and cooled to 0 °C. Triethylamine (7.1 mL, 51 mmol) was added, followed by ethyl chloroformate (4.5 mL, 47 mmol). After 20 min, 2-fluoro-4-methoxyaniline (5.56 g, 39.4 mmol) was added in several small portions. The
10 solution was allowed to warm to room temperature and stirred for 5 hours. The reaction mixture was worked up by diluting with dichloromethane, washing with brine, and drying over MgSO₄. Filtration and concentration provided 15.0 g of an off-white solid, which was granulated with 100 mL of methyl t-butyl ether for 16 hours. Filtration then provided 11.71 g of product (36.9 mmol, 94% yield) as a tan-white
15 solid:

m.p. 168-172 °C

20 ¹H nmr (CDCl₃): 8.28-8.24 (m, 1H), 8.10 (s, 1H), 6.72-6.66 (m, 2H), 3.78 (s, 3H), 3.11-3.06 (m, 2H), 2.86-2.83 (m, 2H), 2.01-1.93 (m, 4H)

MS (Cl): 318 (M+1, 100)

25 **4-Oxo-1,4,5,6,7,8-hexahydro-cyclohepta[b]pyrrole-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide**

General Procedure C (furan carboxamide to pyrrole carboxamide):

30 A 500 mL flask was charged with 4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide from Procedure B (10.0 g, 31.5 mmol), ammonium acetate (12.1 g, 158 mmol), and 20 mL of N-methylpyrrolidinone. The resulting slurry was warmed in a 100 °C oil bath under a static atmosphere of nitrogen for 20 h. After cooling to room temperature, 35 the reaction solution was treated with 180 mL water, added dropwise over a period of 30 min. The resulting solids were granulated for 6 h, then collected via filtration. After 16 h in a vacuum oven at 30 °C, the product was isolated as a tan-brown solid (9.12 g, 28.8 mmol, 91% yield):


40 m.p. 158-159 °C

¹H nmr (CDCl₃): 12.62 (s, 1H), 11.25 (br s, 1H), 8.11-8.06 (m, 1H), 7.53 (br s, 1H), 6.70-6.63 (m, 2H), 3.76 (s, 3H), 2.86-2.81 (m, 2H), 2.76-2.72 (m, 2H), 1.99-1.75 (m, 4H).

5 ¹³C nmr (d₆-DMSO): (14 of 17 lines observed) 201.1, 161.3, 147.3, 126.2, 120.9, 118.2, 115.3, 114.8, 107.9, 56.7, 41.5, 25.8, 23.5, 21.1

Example 2

10



6,6-Dimethyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide

15

Starting with (6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid), prepared from dimedone by Procedure A, and 2-fluoro-4-methoxyaniline, General Procedure B provided the title compound as a white solid:

20 m.p. 174-176 °C

¹H nmr (CDCl₃): 8.23 (t, J = 9, 1H), 8.09 (s, 1H), 6.64 (m, 2H), 3.75 (s, 3H), 2.79 (s, 2H), 2.50 (s, 2H), 1.15 (s, 6H)

25 MS (Cl): 332 (M+1, 100)

6,6-Dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide

30

Starting with (6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide), General Procedure C provided the title compound as a white solid:


5 m.p. 203-205 °C

¹H nmr (CDCl₃): 12.40 (s, 1H), 11.45 (br s, 1H), 8.08 (t, J = 8.8 Hz, 1H), 7.49 (d, J = 1.8 Hz, 1H), 6.72-6.64 (m, 2H), 3.77 (s, 3H), 2.55 (s, 2H), 2.42 (s, 2H), 1.04 (s, 6H).

10 ¹³C nmr (d₆-DMSO): (17 of 18 lines observed) 196.0, 161.3, 156.4, 154.0, 146.9, 127.4, 124.2, 120.3, 118.5, 114.1, 110.0, 102.1, 56.0, 52.0, 36.9, 35.5, 28.2.

Example 3

15



(4-Nitrobenzyl)-methyl-carbamic acid tert-butyl ester

20 To a solution of (tBuO₂C)₂O (24.9 g, 114 mmol) in 100 mL EtOAc was added dropwise a solution of (4-nitrobenzyl)-methylamine (19.0 g, 114 mmol) (*J. Chem. Soc.* 1925, 127, p. 1814) in 19 mL EtOAc. The resulting solution was stirred at room temperature for 60 min, then poured into 100 mL water. The organic phase was separated, dried over MgSO₄, filtered, and concentrated to provide the title compound as a pale yellow oil (30.0 g, 113 mmol, 99% yield):

25

¹H nmr (CDCl₃): (two amide bond rotamers) 8.17-8.15 (m, 2H), 7.35-7.33 (m, 2H), 4.48 (br s, 2H), 2.86-2.80 (overlapping br singlets, 3H), 1.46-1.40 (overlapping br singlets, 9H).

5

(4-Aminobenzyl)-methyl-carbamic acid tert-butyl ester

A Parr bottle was charged with (4-nitrobenzyl)-methyl-carbamic acid tert-butyl ester (30.0 g, 113 mmol), 150 mL EtOAc, and 10% Pd/C (3.0 g, 10 wt%), and shaken 10 under 40 psi hydrogen for 90 min. When hydrogen uptake ceased, the reaction vessel was purged with nitrogen, filtered through celite, and concentrated to provide a tan solid, which was granulated with 300 mL of isopropyl ether to provide the title compound as an off-white solid (17.7 g in two crops, 75 mmol, 66% yield):

15 ¹H nmr (CDCl₃): (two amide bond rotamers) 6.99 (m, 2H), 6.67-6.59 (m, 2H), 4.26 (br s, 2H), 3.68 (br s, 2H), 2.75-2.71 (overlapping br singlets, 3 H), 1.45-1.41 (overlapping br singlets, 9H).

20 **4-[(4-Oxo-4,5,6,7-tetrahydro-benzofuran-3-carbonyl)-amino]-benzyl-methyl-carbamic acid tert-butyl ester**

Starting with (4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid) and (4-aminobenzyl)-methyl-carbamic acid tert-butyl ester, General Procedure B provided 25 the title compound as a white solid:

m.p. 150 °C

30 ¹H nmr (CDCl₃): 8.06 (s, 1H), 7.71 (d, J = 8, 2H), 7.17 (d, J = 8, 2H), 4.35 (fr s, 2H), 2.92 (t, J = 6, 2H), 2.78 (br s, 3H), 2.62 (t, J = 6, 2H), 2.20 (m, 2H), 1.44 (s, 9H).

¹³C nmr (CDCl₃) (16 of 18 lines observed): 197.5, 170.2, 159.1, 148.9, 137.7, 133.6, 127.8, 121.9, 119.9, 116.8, 79.0, 37.8, 33.7, 28.4, 23.5, 22.1

35

4-[(4-Oxo-4,5,6,7-tetrahydro-1H-indole-3-carbonyl)-amino]-benzyl-methyl-carbamic acid tert-butyl ester

Following General Procedure C using (4-[(4-Oxo-4,5,6,7-tetrahydro-benzofuran-3-carbonyl)-amino]-benzyl-methyl-carbamic acid tert-butyl ester) provided 40 the title compound as a pale yellow oil:

¹H nmr (CDCl₃): 7.76 (d, J = 8, 2H), 7.47 (s, 1H), 7.17 (d, J = 8, 2H), 4.36 (br s, 2H), 2.77 (t, J = 6, 2H), 2.76 (br s, 3H), 2.55 (t, J = 6, 2H), 2.08 (t, J = 6, 2H), 1.44 (br s, 9H)

5 ¹³C nmr (CDCl₃) (17 of 18 lines observed): 196.9, 162.5, 148.0, 138.2, 133.3, 128.2, 127.9, 126.2, 120.3, 119.6, 115.6, 79.8, 38.2, 33.8, 28.4, 23.4, 22.8

MS (Cl): 396 (M-1, 100)

10


4-Oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (4-methylaminomethyl-phenyl)-amide

A solution of 4-[(4-Oxo-4,5,6,7-tetrahydro-1H-indole-3-carbonyl)-amino]-benzyl-methyl-carbamic acid tert-butyl ester (5.0 g, 13 mmol) in 50 mL of 95% EtOH was treated with 15 mL of concentrated HCl. After 24 hours, the slurry was cooled to 0 °C; and the solids collected by filtration to provide the title compound as its HCl salt, 3.21 g (9.6 mmol, 74% yield) as a white solid:

20 ¹H nmr (CD₃OD): 12.88 (br s, 1H), 7.82 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 4.15 (s, 2H), 2.91-2.88 (m, 2H), 2.71 (s, 3H), 2.66-2.61 (m, 2H), 2.20-2.15 (m, 2H).

Example 4

25



4-Oxo-5,6-dihydro-4H-cyclopenta[b]furan-3-carboxylic acid (4-ethoxy-phenyl)-amide

30

Starting from 4-oxo-5,6-dihydro-4H-cyclopenta[b]furan-3-carboxylic acid and 4-ethoxyaniline, General Procedure B provided the title compound:

¹H nmr (CDCl₃): 9.68 (s, 1H), 8.15 (s, 1H), 7.65 (d, 2H); 6.88 (d, 2H), 4.02 (q, 2H), 3.14 (m, 4H), 1.4 (t, 3H)

5 **4-Oxo-1,4,5,6-tetrahydro-cyclopenta[b]pyrrole-3-carboxylic acid (4-ethoxy-phenyl)-amide**

Starting from 4-oxo-5,6-dihydro-4H-cyclopenta[b]furan-3-carboxylic acid (4-ethoxy-phenyl)-amide, General Procedure C provided the title compound:


10

m.p. 273-275 °C

¹H nmr (DMSO-d₆): 12.14 (s, 1H), 10.37 (s, 1H), 7.58 (s, 1H), 7.54 (d, 2H), 6.90 (d, 2H), 3.95 (q, 2H), 2.95 (s, 4H), 1.29 (t, 3H)

15

Example 5



20

4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid benzo[1,3]dioxol-5-ylamide

25

Starting from 4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid and benzo[1,3]dioxol-5-ylamine, General Procedure B provided the title compound:

¹H nmr (CDCl₃): 11.79 (s, 1H), 8.09 (s, 1H), 7.48 (s, 1H), 7.06 (d, 1H), 6.77 (d, 1H), 5.94 (s, 2H), 3.06 (t, 2H), 2.82 (t, 2H), 1.98 (br s, 4H)

30


**4-Oxo-1,4,5,6,7,8-hexahydro-cyclohepta[b]pyrrole-3-carboxylic acid
benzo[1,3]dioxol-5-ylamide:**

Starting from 4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid benzo[1,3]dioxol-5-ylamide, General Procedure C provided the title compound:

m.p. 210-212 °C

¹H nmr (DMSO-d₆): 12.51 (s, 1H), 12.02 (s, 1H), 7.48 (s, 1H), 7.46 (s, 1H), 6.95 (d, 1H), 6.86 (d, 1H), 5.98 (s, 2H), 2.97 (br s, 2H), 2.74 (br s, 2H), 1.78 (br s, 4H)

Example 6



15

4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid-(4-methoxy-phenyl)-amide

Starting from 4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid and 4-methoxyaniline, General Procedure B provided the title compound:

¹H nmr (CDCl₃): 11.75 (s, 1H), 8.10 (s, 1H), 7.67 (d, 2H), 6.86 (d, 2H), 3.80 (s, 3H), 3.08 (t, 2H), 2.82 (t, 2H), 1.98 (br s, 4H)


25

4-Oxo-1,4,5,6,7,8-hexahydro-cyclohepta[b]pyrrole-3-carboxylic acid (4-methoxy-phenyl)-amide:

Starting from 4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid-(4-methoxy-phenyl)-amide, General Procedure C provided the title compound:

m.p. 183-185 °C

5 ¹H nmr (DMSO-d₆): 12.42 (s, 1H), 12.02 (s, 1H), 7.60 (d, 2H), 7.48 (s, 1H), 6.90 (d, 2H), 3.72 (s, 3H), 2.95 (br s, 2H), 2.73 (br s, 2H), 1.78 (br s, 4H)



6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid:

Starting with 5-methylcyclohexane-1,3-dione, General Procedure A provided
15 the title compound:

MS (Cl): 193 (M-1, 100)

19 ¹H nmr (CDCl₃): 13.17 (br singlet, 1H), 8.00 (s, 1H), 3.04 (ddd, J = 0.8, 4.4, 17.2, 1H), 2.71-2.59 (m, 2H), 2.57-2.48 (m, 1H), 2.39 (ddd, J = 0.8, 11.2, 16.8, 1H), 1.20 (d, J = 6.4, 3H).

6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid (4-fluoro-phenyl)-amide:

25 Starting from 6-methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid and 4-fluoroaniline, General Procedure B provided the title compound:


29 ¹H nmr (CDCl₃): 11.71 (s, 1H), 8.09 (s, 1H), 7.73 (dd, 2H), 7.01 (t, 2H), 3.03 (dd, 1H), 2.72-2.59 (m, 2H), 2.54 (m, 1H), 2.39 (m, 1H), 1.21 (d, 3H)

6-Methyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (4-fluoro-phenyl)-amide:

33 Starting from 6-methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid (4-fluoro-phenyl)-amide, General Procedure C provided the title compound:

m.p. 262-264 °C

5 ¹H nmr (DMSO-d₆): 12.53 (s, 1H), 12.12 (s, 1H), 7.72 (dd, 2H), 7.54 (s, 1H), 7.18 (t, 2H), 2.92 (dd, 1H), 2.56 (m, 2H), 2.38 (m, 2H), 1.05 (d, 3H)



10

6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid pyridin-4-ylamide:

15

Starting from 6-methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid

and 4-aminopyridine, General Procedure B provided the title compound:

1H nmr (CDCl₃): 12.14 (s, 1H), 8.53 (d, 2H), 8.15 (s, 1H), 7.78 (d, 2H), 3.06 (dd, 1H), 2.77-2.61 (m, 2H), 2.56 (m, 1H), 2.38 (m, 1H), 1.20 (d, 3H)

20

6-Methyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid pyridin-4-ylamide:

25


Starting from 6-methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid

pyridin-4-ylamide, General Procedure C provided the title compound:

m.p. 280-290 °C (dec.)

30

¹H nmr (DMSO-d₆): 12.81 (s, 1H), 12.21 (s, 1H), 8.42 (d, 2H), 7.65 (s, 1H), 7.53 (d, 2H), 2.92 (dd, 1H), 2.55 (m, 2H), 2.38 (m, 2H), 1.07 (d, 3H)



5 **6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid pyridin-3-ylamide**

Starting from 6-methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid and 3-aminopyridine, General Procedure B provided the title compound:


10 ^1H nmr (CDCl_3): 11.90 (s, 1H), 8.90 (s, 1H), 8.38 (d, 1H), 8.31 (d, 1H), 8.13 (s, 1H), 7.28 (m, 1H), 3.06 (dd, 1H), 2.75-2.60 (m, 2H), 2.55 (m, 1H), 2.41 (m, 1H), 1.22 (d, 3H)

15 **6-Methyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid pyridin-3-ylamide**

Starting from 6-methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid pyridin-3-ylamide, General Procedure C provided the title compound:

20 m.p. 225-227 °C

^1H nmr (DMSO-d_6): 12.67 (s, 1H), 12.17 (s, 1H), 8.81 (s, 1H), 8.24 (br s, 1H), 8.13 (d, 1H), 7.58 (s, 1H), 7.37 (m, 1H), 2.88 (dd, 1H), 2.54 (m, 2H), 2.39 (m, 2H), 1.05 (d, 3H)



5 **6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid [6-(2-hydroxyethoxy)-pyridin-3-yl]-amide**

Starting from 6-methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid and 3-amino-6-(2-hydroxyethoxy)-pyridine, General Procedure B provided the title compound:

10

^1H nmr (CDCl_3): 11.72 (s, 1H), 8.48 (s, 1H), 8.12 (d, 1H), 8.11 (s, 1H), 6.79 (d, 1H), 4.42 (t, 2H), 3.97 (t, 2H), 3.62 (br s, 1H), 3.06 (dd, 1H), 2.73-2.60 (m, 2H), 2.53 (m, 1H), 2.39 (m, 1H), 1.05 (d, 3H)

15

6-Methyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid [6-(2-hydroxyethoxy)-pyridin-3-yl]-amide

20

Starting from 6-methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid

20 **[6-(2-hydroxyethoxy)-pyridin-3-yl]-amide**, General Procedure C provided the title compound:


m.p. 183-185 °C

25

^1H nmr (DMSO-d_6): 12.42 (s, 1H), 12.11 (s, 1H), 8.41 (s, 1H), 7.98 (d, 1H), 7.53 (s, 1H), 6.81 (d, 1H), 4.21 (t, 2H), 3.68 (t, 2H), 2.90 (dd, 1H), 2.55 (m, 2H), 2.38 (m, 2H), 1.05 (d, 3H)

Preparation I

Preparation of cycloheptane-1,3-dione:



1-(Trimethylsiloxy)-cyclopentene: A 1 L round bottom flask was charged with cyclopentanone (50.7 g, 0.603 mol) and DMF (250 mL). Triethylamine was added (200 mL, 1.45 mol), followed by dropwise addition of TMSCl (91 mL, 0.72 mol) over 5 min. The solution was then warmed to reflux (90 °C) for 26 h. After cooling to ambient temperature, the mixture was transferred to a separatory funnel, rinsing with 500 mL of hexanes. The solution was washed with water (3 portions of 100 mL each), brine (100 mL), then concentrated to give 110 g of a dark orange oil. ¹H nmr analysis showed the desired product, plus 10-15% of triethylamine. This material was used in the next reaction without further purification.

7,7-Dichloro-1-(trimethylsiloxy)-bicyclo[3.2.0]heptan-6-one: The crude TMS enol ether (2) (0.60 mol) was dissolved in 950 mL of hexanes in a 2 L round bottom flask. Triethylamine (100 mL, 0.72 mol) was added, followed by dichloroacetyl chloride (58 mL, 0.60 mol) as a solution in 450 mL hexanes, dropwise over 2 h. The solution was then stirred at ambient temperature overnight. The reaction mixture was then filtered through fritted glass, rinsing with several 50 mL portions of hexane. The clear solution was concentrated in vacuo to provide 128 g (80% over 2 steps) of product as a dark brown oil. This material was homogeneous by GC/MS and ¹H nmr, save traces of Et₃N and DMF, and was used directly in the next reaction.


Cycloheptane-1,3-dione (1): Dichlorocyclobutanone 3 (128 g, 0.48 mol) was dissolved in 520 mL of 1:1 isopropanol-water in a 2 L, 3-neck flask with an overhead stirrer. Zinc granules (126 g, 1.9 mol, -30+100 mesh) were added in one portion. After 60 min at room temperature, 130 mL of AcOH plus 260 mL of water were added dropwise via addition funnel (ca. 4 mL are added initially, followed by a 10 min hold to check for exotherms; 20 mL were then added, followed by another 10 min hold; once

any exotherm has abated, the remaining acid solution was added dropwise; the entire addition takes 1.5-2 h). After 16 h, the mixture was transferred to a separatory funnel, decanting away from most of the zinc (several small isopropanol rinses were used). The isopropanol-AcOH-water mixture was then extracted with 5 portions of 5 toluene (250 mL each), which are combined and concentrated to provide 51.7 g of product as a dark, orange-brown oil (85% crude mass balance, ca. 85% pure by ^1H nmr). This material is suitable for subsequent reactions, or can be purified by distillation, which provided 29.4 g (0.23 mol, 49% yield) of product as a clear, colorless oil (b.p. 65-75 °C at 1.2 mm). It's spectral properties (^1H nmr, GC/MS) were 10 identical to samples prepared by the oxymercuration route of Chandrasekaran (*Synthetic Communications* 1984, 14, 339-345).

Preparation II

Preparation of 2-fluoro-4-methoxyaniline:

15



1-(2-Fluoro-4-iodo-phenyl)-2,5-dimethyl-1H-pyrrole: A 500 mL round bottom flask was charged with 2-fluoro-4-iodoaniline (53.3 g, 220 mmol), toluene (250 mL), 20 TsOH·H₂O (0.43 g, 2.3 mmol, 1 mol%), and acetonylacetone (30.8 g, 270 mmol, 1.2 eq). The solution was warmed to reflux under Dean-Stark conditions for 1 h, at which point GC/MS and TLC analysis indicate complete conversion to the pyrrole. The solution is cooled to room temperature, washed with aqueous NaHCO₃, dried over MgSO₄, filtered, and concentrated to provide a dark brown oil which crystallized upon 25 standing (crude yield = 72.8 g, 103% of theory). This material was homogeneous by HPLC and ^1H nmr, and was suitable for use in the next reaction. An analytical sample was prepared by dissolving in 210 mL of hot hexanes, cooling, then concentrating to 50% of the original volume. Cooling in an ice bath with rapid stirring provided 35.5 g (49% recovery) of a brown, granular solid (m.p. 68-70 °C). ^1H NMR

(CDCl₃): d 7.43 (t, J = 27 Hz, 2H), 7.13 (t, J = 20 Hz, 1H), 5.94 (s, 2H), 2.02 (s, 6H); ¹³C NMR (CDCl₃) d 158.3 (d, J = 254 Hz), 131.6, 128.9, 127.8 (d, J = 3 Hz), 122.0, 120.3 (d, J = 23 Hz), 106.4, 12.4; MS (EI): m/z 268 (100).

1-(2-Fluoro-4-methoxy-phenyl)-2,5-dimethyl-1H-pyrrole: The crude product from the previous reaction (1-(2-fluoro-4-iodo-phenyl)-2,5-dimethyl-1H-pyrrole, 70.0 g, 222 mmol) was dissolved in 230 mL of MeOH and 70 mL of DMF. To this solution was added NaOMe (35.9 g, 666 mmol, 3.0 eq) and CuCl (3.3 g, 31 mmol, 15 mol%). The resulting mixture was warmed to reflux for 4 h. After cooling to room temperature, isopropyl ether (IPE) (500 mL), 5% aqueous NH₄Cl (220 mL), and water (350 mL) were added, and the mixture was stirred overnight. The mixture was then filtered through celite, the layers were separated, and the aqueous layer extracted with 350 mL of IPE. The combined organic extracts were then washed with 10% aqueous NH₄OH (200 mL), and passed through a pad of silica gel (100 g). Concentration provided a brown oil, which crystallized upon standing (45.2 g, 93% yield).

Recrystallization from 135 mL of hot hexane provided 30.1 g (62% yield) of product as a brown solid, m.p. 67-69 °C. ¹H NMR (CDCl₃): d 7.12 (t, J = 8 Hz, 1H), 6.75 (d, J = 8 Hz, 1H), 6.73 (s, 1H), 5.89 (s, 2H), 3.82 (s, 3H), 1.97 (s, 6H); ¹³C NMR (CDCl₃) (9 of 10 lines observed) d 159.1 (d, J = 260 Hz), 130.7, 129.5, 109.9 (d, J = 3 Hz), 106.0, 105.6, 102.3 (d, J = 25 Hz), 55.7, 12.4; MS (EI): m/z 219 (100).


2-Fluoro-4-methoxyaniline: A 2 L round bottom flask is charged with 1-(2-fluoro-4-methoxy-phenyl)-2,5-dimethyl-1H-pyrrole (60.0 g, 271 mmol), H₂NOH·HCl (188 g, 2.71 mol, 10 eq), EtOH (600 mL), water (300 mL), and Et₃N (76 mL, 0.54 mol), then warmed to reflux for 16 h. After cooling to room temperature, the reaction mixture is slowly poured into 1.7 L of ice-cold 1 N HCl, and washed with two 500 mL portions of IPE. The aqueous phase was then brought to pH 10 by careful addition of 6 N NaOH, and extracted with two 500 mL portions of IPE. The organic extracts were concentrated to provide an oily solid, which was filtered, rinsing with additional IPE (the solid was not related to the aniline product by ¹H nmr analysis, and is presumably some acetonylacetone related by-product of the deprotection). Further concentration of the IPE solution provided a brown oil (36 g, 98% yield), which was recrystallized from 200 mL of hot IPE, to provide 26.8 g (70% yield) of 2-fluoro-4-methoxyaniline 1 as a brown solid, m.p. 46-47 °C (lit. 47-48 °C). Spectral data (¹H

nmr, mass spec) were identical to samples prepared by the literature method (*Aust. J. Chem.* 1972, 25, 2621-2629).

Claims


1. A method for preparing a compound of the formula

5




wherein R¹ and R² are independently selected from hydrogen and C₁ - C₆ alkyl; and Ar is phenyl or heterocycle; or phenyl or heterocycle substituted with up to 10 three substituents selected from C₁ - C₆ alkoxy, C₁ - C₆ alkyl, C₂ - C₆ alkenyl, C₁ - C₆ perfluoroalkyl, C₁ - C₆ alkoxy, C₁ - C₆ perfluoroalkoxy, F, Cl, Br, -O-(CH₂)_k-O-, or (CH₂)_m NR¹R²; wherein
 n is an integer selected from 0 to 2;
 m is an integer selected from 0 to 6; and
 15 k is an integer selected from 1 or 2;
 which comprises:

1) Reacting a compound of the formula



with an excess of an acid chloride or anhydride in a reaction inert 20 solvent containing an excess of an acid acceptor until reaction is complete;
 2) Adding an equivalent amount of NH₂-Ar to the solution of step 1 and holding until reaction is complete.

2. A method for preparing a compound of the formula



which comprises:

- 5 reacting a compound prepared by the method of claim 1 with an excess of ammonium source in a reaction inert solvent at an elevated temperature until reaction is complete.
3. The method of claim 2 wherein Ar is selected from the group consisting of 2-fluoro-4-methoxy phenyl.
- 10 (4-methyl-N-t-butylcarbamic ester)-amino methyl phenyl,
4-ethoxy phenyl or 4-methoxyphenyl,
4-fluorophenyl,
4-pyridyl or 3-pyridyl,
b-(2-hydroxyethoxy)-3-pyridyl, and
- 15 benzo[1, 3] dioxol-5-yl.
4. The method of claim 1 wherein n is 2 and R¹ and R² are hydrogen.
5. The method of claim 1 wherein n is 1 and R¹ and R² are methyl.
6. The method of claim 1 wherein n is one and R¹ and R² are hydrogen.
7. The method of claim 1 wherein n is zero and R¹ and R² are hydrogen.
- 20 8. The method of claim 1 wherein n is 1, R¹ is methyl and R² is hydrogen.
9. A compound prepared by the method of claim 1 which is selected from the group consisting of 4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid, 4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide,

25 6,6-Dimethyl-4-oxo-4,5,6,7-tetrahydro-benofuran-3-carboxylic acid (2-fluoro-4-methoxy-phenyl)-amide,

4-[(4-Oxo-4,5,6,7-tetrahydro-benzofuran-3-carbonyl)-amino]-benzyl-methyl-carbamic acid tert-butyl ester,

4-[(4-Oxo-4,5,6,7-tetrahydro-1H-indole-3-carbonyl)-amino]-benzyl-methyl-carbamic acid tert-butyl ester,

5 4-Oxo-5,6-dihydro-4H-cyclopenta[b]furan-3-carboxylic acid (4-ethoxy-phenyl)-amide, 4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid benzo[1,3]dioxol-5-ylamide,

4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid-(4-methoxy-phenyl)-amide,

10 6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid (4-fluoro-phenyl)-amide,

6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid pyridin-4-ylamide

6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid pyridin-3-ylamide, and

15 6-Methyl-4-oxo-4,5,6,7-tetrahydro-benzofuran-3-carboxylic acid [6-(2-hydroxy-ethoxy)-pyridin-3-yl]-amide.


10. A compound prepared by the method of claim 2 which is selected from the group consisting of 4-Oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (4-methylaminomethyl-phenyl)-amide, and

20 (4-Nitrobenzyl)-methyl-carbamic acid tert-butyl ester.

11. The compound which is (4-Aminobenzyl)-methyl-carbamic acid tert-butyl ester.

12. A method of preparing a compound of claim 2 wherein: Ar is substituted with $-(CH_2)_m NH R^1$ which comprises:

25 reacting a compound of the formula



with water in the presence of acid.

13. A method of claim 1 wherein said acid chloride is ethylchloroformate.

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/IB 98/01672

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D209/42 C07D307/84 A61K31/40 A61K31/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 98 02420 A (NEUROGEN CORPORATION) 22 January 1998 see the whole document ---	1-13
P, A	WO 98 02433 A (NEUROGEN CORPORATION) 22 January 1998 see the whole document ---	1-13
Y	WO 97 34870 A (NEUROGEN CORPORATION) 25 September 1997 see the whole document ---	1-13
Y	WO 97 26243 A (NEUROGEN CORPORATION) 24 July 1997 see the whole document ---	1-13
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

5 February 1999

12/02/1999

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Kyr1akakou, G

INTERNATIONAL SEARCH REPORT

Internat	Application No
PCT/IB 98/01672	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 11885 A (NEUROGEN CORPORATION) 4 May 1995 see the whole document -----	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat	Application No
PCT/IB 98/01672	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9802420	A 22-01-1998	US AU AU HR WO	5750702 A 2832897 A 3660497 A 970385 A 9802433 A	12-05-1998 09-02-1998 09-02-1998 31-08-1998 22-01-1998
WO 9802433	A 22-01-1998	US AU AU HR WO	5750702 A 2832897 A 3660497 A 970385 A 9802420 A	12-05-1998 09-02-1998 09-02-1998 31-08-1998 22-01-1998
WO 9734870	A 25-09-1997	AU EP	2218997 A 0888300 A	10-10-1997 07-01-1999
WO 9726243	A 24-07-1997	US AU CA NO	5804686 A 1746697 A 2243317 A 983315 A	08-09-1998 11-08-1997 24-07-1997 03-09-1998
WO 9511885	A 04-05-1995	US AT AU CA CN CZ DE EP EP ES FI HU JP NO NZ PL SE SK US US	5484944 A 168673 T 8126594 A 2175204 A 1143953 A 9601129 A 69411939 D 0725775 A 0825193 A 2122504 T 961776 A 76064 A 9506082 T 961655 A 275968 A 314136 A 9601563 A 52496 A 5608079 A 5750702 A	16-01-1996 15-08-1998 22-05-1995 11-05-1995 26-02-1997 16-04-1997 27-08-1998 14-08-1996 25-02-1998 16-12-1998 14-06-1996 30-06-1997 17-06-1997 10-06-1996 27-05-1998 19-08-1996 22-05-1996 09-07-1997 04-03-1997 12-05-1998